[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Ising et al., 2019 - Google Patents

NLRP3 inflammasome activation drives tau pathology

Ising et al., 2019

View HTML
Document ID
12159834311467345954
Author
Ising C
Venegas C
Zhang S
Scheiblich H
Schmidt S
Vieira-Saecker A
Schwartz S
Albasset S
McManus R
Tejera D
Griep A
Santarelli F
Brosseron F
Opitz S
Stunden J
Merten M
Kayed R
Golenbock D
Blum D
Latz E
Buée L
Heneka M
Publication year
Publication venue
Nature

External Links

Snippet

Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline. The NLRP3 inflammasome …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids

Similar Documents

Publication Publication Date Title
Ising et al. NLRP3 inflammasome activation drives tau pathology
Wendeln et al. Innate immune memory in the brain shapes neurological disease hallmarks
Dejanovic et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies
Joshi et al. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration
Zhang et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency
Fleming et al. Autophagy in neuronal development and plasticity
Sorrentino et al. Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity
Gorantla et al. Tau protein squired by molecular chaperones during Alzheimer’s disease
Ota et al. REDD1 is essential for stress-induced synaptic loss and depressive behavior
Rhinn et al. Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Dickey et al. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically
Moreno et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice
Jeong et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway
Cheng et al. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP
Jiménez-Loygorri et al. Mitophagy curtails cytosolic mtDNA-dependent activation of cGAS/STING inflammation during aging
Auerbach et al. Mutations causing syndromic autism define an axis of synaptic pathophysiology
Do Carmo et al. Rescue of early bace-1 and global DNA demethylation by S-adenosylmethionine reduces amyloid pathology and improves cognition in an Alzheimer’s model
Chen et al. Contribution of neural cell death to depressive phenotypes of streptozotocin-induced diabetic mice
Garcia-Esparcia et al. Dementia with Lewy bodies: molecular pathology in the frontal cortex in typical and rapidly progressive forms
Arreola et al. Microglial dyshomeostasis drives perineuronal net and synaptic loss in a CSF1R+/− mouse model of ALSP, which can be rescued via CSF1R inhibitors
Li et al. Reducing histone acetylation rescues cognitive deficits in a mouse model of Fragile X syndrome
Yamamoto et al. Rosmarinic acid suppresses tau phosphorylation and cognitive decline by downregulating the JNK signaling pathway
Suzuki et al. FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion
Dennissen et al. Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280
Ikenaka et al. A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease